| Jul 10 |
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
|
| Jul 2 |
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
|
| Jul 2 |
FTC investigates Teva over contested product patents
|
| Jul 1 |
Update: Market Chatter: Teva Pharmaceuticals Faces FTC Probe on Patent Listings
|
| Jul 1 |
Correction: Top Midday Stories: Boeing to Acquire Spirit AeroSystems; Robinhood Acquires Pluto; FTC Probes Teva; BlackRock Acquires Preqin; SCOTUS Grants Trump Some Immunity
|
| Jul 1 |
Teva focus of FTC investigation over inhaler patents
|
| Jun 28 |
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
|
| Jun 25 |
Teva to pay $750M as part of tax deal with Israel
|
| Jun 25 |
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
|
| Jun 24 |
Teva launches authorized generic of Victoza for diabetes, cardiovascular treatment in the U.S.
|
